Genetic ablation and therapeutic inhibition of CD70 in NPC cells undermined Treg abundance and suppressive activity, thus enhancing anti-tumor immunity mediated by CD8+ T cells and the efficacy of anti-PD-1 treatment (Fig. 7n), as comprehensively validated in cell lines, primary culture, organoids, PDX, and humanized mouse models. The gene discussed is CD70; the disease is nasopharyngeal carcinoma.